WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Friday, January 25, 2019

Cognitive Impairment Tests to Assess Dementia Risk Can Be Easier, Study Shows

JANUARY 24, 2019 BY CATARINA SILVA IN NEWS.





A shorter, simpler version of testing to diagnose mild cognitive impairment in Parkinson’s disease is just as effective as a lengthier evaluation at predicting the risk of developing Parkinson’s disease dementia, a report shows.
Both cognitive decline and dementia are recognized as non-motor complications of Parkinson’s with significant clinical impact. Evidence suggests that mild cognitive impairment is a risk factor for Parkinson’s disease dementia (PDD).
The International Parkinson and Movement Disorder Society (MDS) has formulated two levels of criteria for diagnosing Parkinson’s-related mild cognitive impairment. Levels 1 and 2 differ in their methods of assessment, level of diagnostic certainty, and extent of clinical characterization.
Level 1 is comprised of a simpler, shorter series of cognitive tests, while level 2 entails a more extensive neuropsychological evaluation.
One study has shown that using level 2 criteria to assess mild cognitive impairment — which considered age, sex, years of education, depression and the severity of motor symptoms — can be effective at confirming an increased risk of patients developing dementia.
The University of Amsterdam researchers evaluated the prognostic value of testing mild cognitive impairment, using level 1 criteria as indicators of PDD.
“Comprehensive neuropsychological testing is not always possible because of time, cost, or patients’ inability to cooperate with a long assessment,” they said.
Looking at eight international studies, totaling 1,045 patients, they analyzed demographic and clinical data including age, sex, years of education, disease duration and neuropsychological examinations, based on the Unified Parkinson’s Disease Rating Scale (UPDRS) part III (motor tests), the Movement Disorder Society (MDS)-UPDRS III score, the Hoehn and Yahr scale (used to measure symptom progression), and an indicator of patient depression.
Level 1 criteria were applied, with one test of each of the five cognitive domains: attention, executive function— the ability to manage and organize thoughts, actions, and feelings — memory, visuospatial function, and language.
Survival analysis evaluated how each factor contributed to the risk of PDD.
In an initial evaluation17% of the patients were diagnosed with mild cognitive impairment. Median follow-up was 2.8 years and 151 out of the 1,045 (14.4%) patients developed dementia.
Only 9% of those without cognitive impairment at the beginning of the study developed dementia during follow-up, compared to 77% in the mild cognitive impairment group.
Worse performance in level 1 testing was associated with a higher risk of developing PDD dementia.
The evaluation also revealed that increasing age, male sex, and the severity of Parkinson’s motor symptoms independently heighten this risk.
Importantly, the study found that both levels of criteria had similar discriminant ability, meaning that the less extensive level 1 testing was effective at determining PDD risk.
Researchers also reported that level 1 criteria identified fewer mild cases, and associated them with relatively higher risk ratios, which they said could be attributed to the rating system used.  Level 1 criteria measures greater cognitive decline, when using the same cutoff as level 2 criteria.  For example, in level 1, at least two out of five tests need to show impairment, compared to at least two out of 10 tests in level 2
“In conclusion, level I PD-MCI [mild cognitive impairment] criteria classification, based on a brief neuropsychological assessment, confers an independent contribution to the hazard of PDD while taking age, sex, education, PD motor sign severity, and depression into account. This finding supports the role of level I PD-MCI as a risk factor for PDD,” they wrote.
https://parkinsonsnewstoday.com/2019/01/24/tests-mild-cognitive-impairment-dementia-risk-easier-study-says/

No comments:

Post a Comment